Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 8—August 2011

Dispatch

Multidrug-Resistant Pandemic (H1N1) 2009 Infection in Immunocompetent Child

Alireza Eshaghi, Samir N. Patel, Alicia Sarabia, Rachel R. Higgins, Alexei Savchenko, Peter J. Stojios, Yan Li, Nathalie Bastien, David C. Alexander, Donald E. Low, and Jonathan B. GubbayComments to Author 
Author affiliations: Author affiliations: Ontario Agency for Health Protection and Promotion, Toronto, Ontario, Canada (A. Eshaghi, S.N. Patel, R.R. Higgins, D.C. Alexander, D.E. Low, J.B. Gubbay); The Credit Valley Hospital, Mississauga, Ontario, Canada (A. Sarabia); University of Toronto, Toronto (A. Savchenko, P.J. Stojios, D.C. Alexander, D.E. Low, J.B. Gubbay); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (Y. Li, N. Bastien); Mount Sinai Hospital, Toronto (D.E. Low, J.B. Gubbay); The Hospital for Sick Children, Toronto (J.B. Gubbay)

Main Article

Table 1

Susceptibility of I223R mutant and control pandemic (H1N1) 2009 strains to oseltamivir carboxylate in the chemiluminescent NA inhibition assay, Canada, 2010*

Virus strain
NA mutation†
Susceptibility
OAHPP testing

NML testing
Mean IC50 ± SD, nmol
-fold increase
Mean IC50 ± SD, nmol
-fold increase
A/Ontario/313762/2009 I223R 9.49 ± 2.19‡ 28 10.95 ± 2.5‡ 22
A/California/07/2009-like control Wild type 0.34 ± 0.14§ 0.49 ± 0.31§
Oseltamivir-resistant control H275Y 57.1 ± 21.48¶ 168 81.42 ± 24.1¶ 166

*NA, neuraminidase; OAHPP, Ontario Agency for Health Protection and Promotion; NML, National Microbiology Laboratory; IC50, 50% inhibitory concentration.
†Mutations presented in N1 numbering.
‡For 7 and 4 experiments done by OAHPP and NML, respectively.
§For 17 and 1,446 experiments done by OAHPP and NML, respectively.
¶For 13 and 14 experiments done by OAHPP and NML, respectively.

Main Article

TOP